Kiniksa Pharmaceuticals(KNSA)
MA - LexingtonPharmaceutical
Focus: Kiniksa is a public specialty pharma focused on biologics and monoclonal antibodies for rare inflammatory diseases, anchored by the approved IL-1 inhibitor ARCALYST. The company operates as a mid-cap with growing pipeline depth across pericarditis, autoimmune, and dermatologic indications.
Profile data last refreshed 5h ago · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Open Jobs
20
Should You Work at Kiniksa Pharmaceuticals?
AI assessmentKiniksa suits biotech professionals seeking focused immunology exposure with near-term pericarditis upside, but carry significant binary risk from single-product dependency and unproven pipeline transition.
Why Work Here
- Focused pipeline with Phase 3 momentum in recurrent pericarditis (rilonacept), a high-unmet-need orphan indication showing near-term commercial potential
Data completeness
6/9 — Partial
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$270M
Key Products
$25M Part DDeclining
LOE Approaching
IL-1α/IL-1β trap approved for rare autoinflammatory syndromes; only approved revenue driver, currently under patent exclusivity but loss-of-exclusivity date imminent.
Help build intelligence for Kiniksa Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.